Survival outcomes of the use of adjuvant chemotherapy in resected esophagus cancer after neoadjuvant chemoradiotherapy
European Journal of Surgical Oncology · 2026
DOI: 10.1016/j.ejso.2025.111177 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Te-Min Ke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Esophagectomy. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cheng Kung University Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the standard treatment for esophageal cancer, but the role of adjuvant chemotherapy remains unclear. This study investigates the survival benefits of adjuvant chemotherapy in patients undergoing nCRT and surgery. METHODS: A total of 1212 esophageal cancer patients who underwent nCRT and surgery, with or without adjuvant chemotherapy, between January 2008 and December 2018 were identified from the Taiwan Cancer Registry and National Health Insurance Research Database. The Cox regression analysis was utilized to evaluate the impact of adjuvant chemotherapy on 5-year mortality rates. RESULTS: Of the 1212 patients, 276 (22.8 %) received adjuvant chemotherapy, while 936 (77.2 %) did not. The most used chemotherapy regimens were cisplatin and 5-FU. Younger age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; Department of Information Management, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
- Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; Institute of Precision Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan; Trans-Omic Laboratory for Precision Medicine, Precision Medici…
- Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan; Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-se…
- Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan; Department of Cosmetic Science, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan. Electronic addre…
Förderung
- National Cheng Kung University Hospital
Zitieren
APA
Ke, T. M., Lin, T., Chow, W. H., Ho, C. H., Chen, Y. C., Li, C. F., Yang, C. C., & Kuo, Y. H. (2026). Survival outcomes of the use of adjuvant chemotherapy in resected esophagus cancer after neoadjuvant chemoradiotherapy. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111177
Vancouver
Ke TM, Lin T, Chow WH, Ho CH, Chen YC, Li CF, et al. Survival outcomes of the use of adjuvant chemotherapy in resected esophagus cancer after neoadjuvant chemoradiotherapy. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111177
BibTeX
@article{Ke2026,
author = {Ke, Te-Min and Lin, Tung and Chow, Wan-Hsuan and Ho, Chung-Han and Chen, Yi-Chen and Li, Chien-Feng and Yang, Ching-Chieh and Kuo, Yu-Hsuan},
title = {Survival outcomes of the use of adjuvant chemotherapy in resected esophagus cancer after neoadjuvant chemoradiotherapy},
journal = {European Journal of Surgical Oncology},
year = {2026},
doi = {10.1016/j.ejso.2025.111177}
}
EUVIMED